Brief: Aprea Therapeutics Announces Dosing Of First Patient In Phase 1/2a Clinical Trial Of ATRN-119
11/01/2023 13:47
Jan 11 (Reuters) - Aprea Therapeutics Inc APRE.O :
* APREA THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN
PHASE
1/2A CLINICAL TRIAL OF ORAL ATR INHIBITOR ATRN-119 FOR THE
TREATMENT OF ADVANCED SOLID TUMORS
* APREA THERAPEUTICS - LOOK FORWARD TO SHARING PRELIMINARY
DATA
FROM STUDY THROUGHOUT 2023
Source text for Eikon: ID:nGNX8sS4xd
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing